COMy 2016 | Trial results and drug combinations for bortezomib in multiple myeloma
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium discusses the role of bortezomib in relapsed/refractroy multiple myeloma (MM). Prof Delforge, discusses the various trials that showed the superiorty of the proteasome inhibitor bortezomib in terms of response and time to progression. According to Prof Delforge, bortezomib is an ideal backbone and is combined with dexamethasone alone, or dexamethasone and a third agent, for example chemotherapy or immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, pomalidomide. Bortezomib can further be combined with histone deacetylase (HDAC) inhibitors like vorinostat and panobinostat. Prof Delforge discusses trials results for the various combinations. For the future, the expectations for the combination of bortezomib with monoclonal antibodies such elotuzumab and daratumumab, are high.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
- histone deacetylase inhibitors
- immunomodulatory drugs
- monoclonal antibodies
- multiple myeloma
- proteasome inhibitors
- relapsed/refractroy multiple myeloma
- time to progression
- University Hospital Leuven
Get great new content delivered to your inboxSign up